COVId-19 Highlights: Impact on Plasma Therapy in Healthcare Industry
Plasma medications are produced from human blood plasma (plasma). Plasma can be obtained from administration of whole blood (recovered plasma) or apheresis procedures (plasma source). The source is plasma a wide range of medicinal therapies products used for treatment and the prevention of various treatment-causing injuries and diseases often associated with a protein deficiency state. Convalescent Plasma Therapy (CP), a classic adaptive immunotherapy, has been used in the prevention and treatment of many infectious diseases for over a century. In the past two decades, CP therapy has been successfully used in the treatment of the 2009 SARS, MERS and H1N1 pandemic with satisfactory efficacy and safety. In 2014, the World Health Organization (WHO) recommended the use of convalescent plasma therapy for the treatment of patients with antibody-rich plasma in those recovering from Ebola virus disease.
This study specially analyses the impact of Covid-19 outbreak on the Plasma Therapy, covering the supply chain analysis, impact assessment to the Plasma Therapy market size growth rate in several scenarios, and the measures to be undertaken by Plasma Therapy companies in response to the COVID-19 epidemic.
Get FREE Sample PDF (including COVID19 Impact Analysis) of Market Report @ https://www.databridgemarketresearch.com/covid-19-resources/covid-19-impact-on-plasma-therapy-in-the-healthcare-industry
Market Analysis: Global Plasma Therapy Market
Global plasma therapy market is registering a healthy CAGR of 15.7% in the forecast period of 2019-2026. This rise in the market value can be attributed to the growth in the use of planet rich plasma for the treatment of various diseases that drives the growth of the industry and increasing incidents of sports injuries.
The Plasma Therapy Market report is an investigative study of the market, along with an analysis of its key segments. The report is constructed through a thorough primary and secondary research. The insightful data of the market is generated through interviews and data collection from the industry experts and professionals. The study is an extensive document of the key aspects of the markets, including trends, segmentation, growth prospects, opportunities, challenges, and competitive analysis.
The report is updated with the impact of the currently unfolding COVID-19 pandemic. The pandemic has dynamically affected the key segments of the market and has changed the growth pattern and demands in the Plasma Therapy market. The report covers extensive analysis of these changes and provides an accurate forecast estimation of the market growth after the impact of the pandemic.
Latest research report on Plasma Therapy Market delivers a comprehensive study on current market trends. The outcome also includes revenue forecasts, statistics, market valuations which illustrates its growth trends and competitive landscape as well as the key players in the business.
The regional analysis of Global Plasma Therapy Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America region is the leading region across the world in terms of market share. Whereas, owing to countries viz. India, Indonesia, China, and Japan, the Asia Pacific region is expected to exhibit higher growth rate / CAGR over the forecast period 2018-2025.
Global Plasma Therapy Market: Application Segment Analysis
- Orthopedics
- Dermatology
- Dental
- Cardiac Muscle Injury
- Nerve Injury
- Others
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Strategic decisions of manufacturers
Collaboration, agreements, strategic initiatives by market players such as CSL Behring, Takeda Pharmaceutical Company Limited, Biotest, Octapharma in the plasma therapy market will help them expand their market and expand their product portfolio. This, in turn, will help increase product demand among consumers, thus increasing future sales.
The plasma therapy manufacturers are taking much strategic decision to cope up with this current pandemic COVID-19. Global Plasma Leaders are collaborating to accelerate the development of potential COVID-19 hyperimmune therapy. Biotest, BPL, LFB and Octapharma have partnered to form an alliance formed by CSL Behring (ASKS: CSL / USOTC: CSLLI) and Takeda Pharmaceutical Company Limited (TSE: 4502 / NISE: TAK) to develop potential plasma therapy for COVID treatment-19. The alliance will begin immediately with the research development of a single, non-branded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin drug with the potential to treat individuals with serious complications of COVID-19. The collaboration will leverage the cutting edge expertise and work that companies already do. Alliance experts will begin collaborating on key aspects such as plasma collections, clinical trial development, and manufacturing.